Advertisement

Topics

Cellectis advances CAR-T therapy study with dosing of its first participant

04:42 EDT 21 Aug 2017 | SmartBrief

The early-stage clinical trial that will evaluate the efficacy and safety of UCART123, Cellectis' chimeric antigen receptor T -More

Original Article: Cellectis advances CAR-T therapy study with dosing of its first participant

NEXT ARTICLE

More From BioPortfolio on "Cellectis advances CAR-T therapy study with dosing of its first participant"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...